News

AgroSpheres Named on Both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 Lists by TIME Magazine

AgroSpheres has been named on both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 lists. These prestigious awards are presented by TIME and Statista Inc., the leading statistics portal and industry ranking provider. The award lists were announced on March 25th, 2025, and can be viewed on TIME’s website.

Statista ranked the winners based on three evaluation criteria:

  • Positive environmental impact: The scoring is based on impact data such as the quality and impact of their product/service portfolio, as well as the expertise of their leadership team provided by HolonIQ
  • Financial strength: The scoring is based on the analysis of financial data points e.g., revenue, employee or funding information
  • Innovation drive: The scoring is based on the Patent Asset Index featured in LexisNexis® Intellectual Property Solutions

“Being recognized by TIME as one of the top GreenTech companies in both the U.S. and globally is a testament to the power of science-driven innovation in reshaping agriculture and our strong business fundamentals,” said Payam Pourtaheri, Co-Founder and CEO of AgroSpheres. “We have built a solid financial foundation to support the rapid commercialization of our bio-based solutions, ensuring long-term impact for growers and the environment. This recognition reinforces our mission to lead the way in the bio-based revolution.”

“Innovation drive and impact go hand in hand,” added Ameer Shakeel, AgroSpheres’ Co-Founder and CTO. “We have built an end-to-end technology platform, rooted in cutting-edge science, novel active ingredients and a strong intellectual property portfolio. Our advancements in encapsulation and delivery technologies are paving the way for greener, more effective crop protection solutions across the industry. As we scale our operations to commercialization, this honor from TIME highlights the growing momentum behind sustainable agriculture worldwide.”

In support of the research, Statista gathered data from company applications, annual reports, media monitoring, and other public sources. Additionally, Statista worked with specialized data partners HolonIQ and LexisNexis® Intellectual Property Solutions to further strengthen the data quality.

Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, relevant business data, and various market and consumer studies and surveys.

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like